Breaking Finance News

A statement released earlier today by Zacks Investment Research about Teleflex Incorporated (NYSE:TFX) ups the target price to $223.00

In a report released on 05/24/2017 Zacks Investment Research increased the stock price target of Teleflex Incorporated (NYSE:TFX) to $223.00 reporting a possible upside of 0.12%.

Just yesterday Teleflex Incorporated (NYSE:TFX) traded 0.49% higher at $198.80. Teleflex Incorporated’s 50-day average is $227.58 and its two hundred day average is $209.02. With the last stock price down 18.47% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time. 42,420 shares of the stock were exchanged, down from an average trading volume of 259,425

See Chart Below

Teleflex Incorporated (NYSE:TFX)

Teleflex Incorporated has a 52 week low of $136.53 and a 52 week high of $248.40 with a P/E ratio of 47.36 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 11 analysts have released a report on Teleflex Incorporated. The 12-month target is $167.36 with four equity analysts rating the company a strong buy, 5 brokerages rating the stock a buy, 3 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Teleflex Incorporated (NYSE:TFX)

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company's products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.